EUVIMEDEUVIMED entdecken
Crossref

Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting

G Fekadu, Y Wang, J H S You

The International Journal of Tuberculosis and Lung Disease · 2024

DOI: 10.5588/ijtld.23.0163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2024. Verfasst von G Fekadu und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Tuberculosis, Nitroimidazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

Recent clinical findings reported improvement in the treatment outcomes of highly resistant TB (HDR-TB) with the pretomanid (Pa) based regimen. This study aimed to evaluate the cost-effectiveness of the Pa-based regimen for HDR-TB treatment from the perspective of the healthcare sector in the United States.





METHODS

A lifelong decision-analytic model was constructed to simulate potential treatment outcomes of 1) the bedaquiline-Pa-linezolid (BPaL) regimen, and 2) the bedaquiline-linezolid (B-L) based regimen in a hypothetical cohort of adult patients with HDR-TB. Primary model outputs were TB-related direct medical costs, quality-adjusted life-years (QALYs) and incremental cost per QALY gained (ICER).





RESULTS

In the base-case analysis, the BPaL regimen gained 3.0054 QALYs and saved costs by USD60,433 when compared to the B-L-based regimen. In the probabilistic sensitivity analysis, the BPaL regimen gained higher QALYs at a lower cost in 80.3% of the time, and gained higher QALYs at a higher cost with ICER less than the willingness-to-pay (WTP) threshold (100,000 USD/QALY) in 19.0% of the simulations. The probability of the BPaL regimen being cost-effective was higher than the B-L-based regimen throughout the variation of WTP.





CONCLUSION

BPaL therapy is likely the cost-effective option for HDR-TB treatment from the US healthcare sector perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisNitroimidazolesAdultHumansUnited StatesCost-Benefit AnalysisLinezolidQuality-Adjusted Life Years

Substanzen

pretomanidLinezolidNitroimidazoles

Zitieren

APA

Fekadu, G., Wang, Y., & You, J. H. S. (2024). Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.23.0163

Vancouver

Fekadu G, Wang Y, You JHS. Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting. The International Journal of Tuberculosis and Lung Disease. 2024. doi:10.5588/ijtld.23.0163

BibTeX
@article{Fekadu2024,
  author = {Fekadu, G and Wang, Y and You, J H S},
  title = {Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2024},
  doi = {10.5588/ijtld.23.0163}
}
Kostenlos starten →